Expert Insights: Evolving Treatment Landscape in NDMM

Opinion
Video

Panelists discuss how the treatment paradigm for newly diagnosed multiple myeloma (NDMM) has evolved from conventional chemotherapy to modern regimens incorporating novel agents like proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies while highlighting persistent challenges including optimizing treatment sequencing and addressing high-risk disease.

Video content above is prompted by the following:

  • Provide a brief historical overview of the therapeutic landscape for transplant-eligible and ineligible NDMM.
  • How has the landscape evolved since, and what challenges/unmet needs remain?
Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
1 expert is featured in this series.
7 experts are featured in this series.
7 experts are featured in this series.
5 experts are featured in this series
3 panelists
Related Content
Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma

Daratumumab Combo Yields Significantly Higher MRD Negativity in Multiple Myeloma

ONCOLOGY Staff
December 22nd 2025
Article

C. Ola Landgren, MD, PhD, and Noopur Raje, MD, discussed results from the ADVANCE trial of DKRd in patients with newly diagnosed multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Patients 70 years and older with newly diagnosed multiple myeloma experienced higher response rates and prolonged survival with Isa-Rd vs Rd alone.

Higher MRD Negativity Rates Occur With Isa-RD in Older NDMM Population

Roman Fabbricatore
December 19th 2025
Article

Patients 70 years and older with newly diagnosed multiple myeloma experienced higher response rates and prolonged survival with Isa-Rd vs Rd alone.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The decision is based on results from the phase 3 MajesTEC-3 trial, which showed a PFS benefit with the teclistamab combination in patients with pretreated multiple myeloma.

FDA Grants National Priority Voucher to Teclistamab/Daratumumab in RRMM

Tim Cortese
December 15th 2025
Article

The decision is based on results from the phase 3 MajesTEC-3 trial, which showed a PFS benefit with the teclistamab combination in patients with pretreated multiple myeloma.

Alan Pliskin and Mary Kay Yamamoto discuss their journey through multiple myeloma treatment, emphasizing the importance of knowledge, positivity, and quality of life.

How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?

Tim Cortese
December 14th 2025
Article

Alan Pliskin and Mary Kay Yamamoto discuss their journey through multiple myeloma treatment, emphasizing the importance of knowledge, positivity, and quality of life.